WELLNESS
06/06/2013 03:29 pm ET Updated Aug 06, 2013

Narrowly-Divided FDA Panel Votes To Modify Avandia Restrictions

MIAMI - JULY 14:  A bottle and pills of the diabetes drug, Avandia are seen on July 14, 2010 in Miami, Florida. Today, the U.
MIAMI - JULY 14: A bottle and pills of the diabetes drug, Avandia are seen on July 14, 2010 in Miami, Florida. Today, the U.S. Food and Drug Administration panel voted to recommend that GlaxoSmithKline PLC's (GSK) diabetes drug, Avandia, remain on the market despite concerns that the product could raise the risk of heart attacks. (Photo by illustration Joe Raedle/Getty Images)

WASHINGTON, June 6 (Reuters) - A narrowly divided U.S. Food and Drug Administration panel of outside experts on Thursday voted to modify market restrictions on GlaxoSmithKline's diabetes drug Avandia, the one-time blockbuster at the center of one of the biggest drug controversies in recent years.

Thirteen members of the advisory panel favored modification, while seven others voted to remove the restrictions altogether and five panel members favored keeping current safeguards in place without changes. One committee member voted to withdraw Avandia from the market altogether.

HuffPost

BEFORE YOU GO

PHOTO GALLERY
What Affects Diabetes Risk?